Fresenius SE & Co. (OTCMKTS:FSNUY) Short Interest Up 14,572.5% in April
by Scott Moore · The Cerbat GemFresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) was the recipient of a large growth in short interest during the month of April. As of April 30th, there was short interest totaling 144,231 shares, a growth of 14,572.5% from the April 15th total of 983 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily trading volume, of 357,947 shares, the days-to-cover ratio is currently 0.4 days.
Fresenius SE & Co. Price Performance
FSNUY stock traded down $0.33 during trading on Monday, hitting $11.79. The company had a trading volume of 253,104 shares, compared to its average volume of 96,687. The company has a fifty day moving average price of $13.07 and a two-hundred day moving average price of $14.14. The company has a current ratio of 1.32, a quick ratio of 1.00 and a debt-to-equity ratio of 0.47. The company has a market cap of $26.56 billion, a P/E ratio of 15.72 and a beta of 0.68. Fresenius SE & Co. has a fifty-two week low of $11.28 and a fifty-two week high of $33.93.
Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.24 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.01). The company had revenue of $6.75 billion during the quarter, compared to analyst estimates of $6.79 billion. Fresenius SE & Co. had a net margin of 6.55% and a return on equity of 10.29%. Equities research analysts expect that Fresenius SE & Co. will post 1.05 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
FSNUY has been the topic of a number of research analyst reports. Morgan Stanley reaffirmed an “overweight” rating on shares of Fresenius SE & Co. in a report on Monday, April 20th. Citigroup reaffirmed a “buy” rating on shares of Fresenius SE & Co. in a report on Tuesday, February 3rd. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has an average rating of “Buy”.
Read Our Latest Stock Report on Fresenius SE & Co.
About Fresenius SE & Co.
Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.
The company operates through four main business segments.